Pharmena (WAR:PHR) Total Equity: zł9.17 Mil (As of Mar. 2026)


WAR:PHR Pharmena SA WAR:PHR
57 GF Score
Price zł3.13
GF Value zł5.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Pharmena Total Equity?

Pharmena WAR:PHR -0.95% 57 Total Equity is zł9.17 Mil as of Mar. 2026. GuruFocus rates WAR:PHR with a GF Score™ of 57/100 and a GF Value™ of zł5.74 (Possible Value Trap). The stock has 4 warning signs investors should review.

Pharmena's total equity for the quarter that ended in Mar. 2026 was zł9.17 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pharmena Total Equity Historical Data

* Premium members only.

The historical data trend for Pharmena's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmena Total Equity Chart

Pharmena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.12 -6.79 23.15 12.42 9.65

Pharmena Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.93 11.23 10.54 9.65 9.17
WAR:PHR
57GF Score
Pharmena SA WAR:PHR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmena Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pharmena's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=10.921-1.273
=9.65

Pharmena's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=10.294-1.127
=9.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł9.17 Mil mean?
Pharmena (WAR:PHR) has a Total Equity of zł9.17 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Pharmena and its competitors.
Is Pharmena's Total Equity too high?
Pharmena's current Total Equity is zł9.17 Mil. Overall, Pharmena has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's Total Equity compare to VRTX and REGN?
Pharmena's Total Equity of zł9.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pharmena and its competitors. Pharmena's current Total Equity is zł9.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.74, compared to a current price of zł3.13 — trading 45.5% below its estimated fair value. The current Total Equity is zł9.17 Mil. Pharmena's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current Total Equity is zł9.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmena (WAR:PHR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmena stock appears to be undervalued. The current stock price of zł3.13 is trading 45.5% below its estimated GF Value™ of zł5.74. GuruFocus considers Pharmena to be Possible Value Trap.

Key valuation signals for WAR:PHR:

  • Total Equity: zł9.17 Mil
  • GF Value™: zł5.74 vs. price of zł3.13 (45.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmena Business Description

Address Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
57GF Score

Get the complete analysis for WAR:PHR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.13
Price
zł5.74
GF Value